Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy

NCT03092011 ↗

Phase 4 Active not recruiting 69 enrolled The Cooper Health System

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to show non-inferiority between two medications used for medical treatment of withdrawal seen in Neonatal Abstinence Syndrome (NAS), Clonidine and Morphine Sulfate (used in routine care) on length of treatment for NAS .

Timeline

Start: 2018-02-21
Primary completion: 2024-10-01
Completion: 2026-12-01

Publications

Zankl A, Martin J, Davey JG, Osborn DA. Opioid treatment for opioid withdrawal in newborn infants. Cochrane Database Syst Rev. 2021 Jul 7;7(7):CD002059. doi: 10.1002/14651858.CD002059.pub4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clonidine	Other / unclassified	0.38 ug/kg	Oral
Subject	Clonidine	Other / unclassified	0.5 ug/kg	Oral
Comparator	Morphine	Other / unclassified	0.03 mg/kg	Oral
Comparator	Morphine	Other / unclassified	0.04 mg/kg	Oral

Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy

Summary

Timeline

Publications

Drugs

Indications